hyun_seoul said:

The liver data is among the strongest non-weight findings in the class.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

steph_laguna said:

Steady state is the thing most people miss.

This answered a question I did not know how to ask. Sending this to two other people who asked me the same thing last week.

hyun_seoul said:

The liver data is among the strongest non-weight findings in the class.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

That is the short version; the long version is somebody else's post.

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. No action needed from anybody.